Good morning. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations, and projections of future events. While management believes its assumptions, expectations and projections are reasonable in view of the currently available information, your question not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and Risk Factors sections of the company's Form 10-K for the year of 2022 which was filed March 24, 2023, and its other filings with the SEC which are available on the Investor Relations section of Jaguar's Web site. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise. Additionally, please note that the Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it's my pleasure to turn the call over to Lisa Conte, Jaguar Health's, Founder, President and Chief Executive Officer. Lisa, the floor is yours.

Thank you. Thank you all for joining our earnings webcast for the second quarter of 2023. And welcome to all of you. And as you just heard, my name is Lisa Conte. I'd like to begin today's call with a high-level overview of the Jaguar family of companies, and then I will provide updates on our key near-term initiatives and milestones. Following my comments, Carol Lizak, Jaguar's Chief Financial Officer will provide a detailed recap of the key financial results for the second quarter of 2023. Although, spoiler alert, we're very pleased to report that the net revenue increased 36% in Q3 2023 versus the first quarter of this year. Jaguar, as if you know the company, is a commercial stage pharmaceuticals company focusing on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people primarily, and animals, with GI distress, specifically overactive bowl, which is fresh lexicon I'm introducing today. There is a range of interpretations when we use the word diarrhea. With the terminology, overactive bowl, we include systems such as chronic, debilitating, loose, watery stools or as some will refer to diarrhea, also GI urgency and unpredictability, and GI incontinence, all disrupting and disturbing to the patient, their quality of life, and their health. I'll now review also the relationship of the Jaguar family companies, Napo Pharmaceuticals, wholly owned by Jaguar, focuses on developing and commercializing the human prescription pharmaceuticals we develop. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, our ongoing pivotal Phase 3 clinical trial for preventative treatment of chemotherapy-induced overactive bowel, CIOB, and that is the acronym that we're all going to start to get used to; CIOB in adults with cancer on targeted therapy. Jaguar family company, Napo Therapeutics, as opposed to Napo Pharmaceuticals,…

Well, thank you, Lisa. And thank you all for joining our webcast today. I'll begin my review of our financials for the second quarter of 2023. Prescription product net revenue was approximately $2.7 million in the second quarter of 2023, representing an increase of 36% compared to prescription product net revenue in the first quarter of 2023, which totaled approximately $2 million. And a decrease of approximately 8% over prescription product net revenue in the second quarter of 2022 which totaled approximately $2.9 million. Mytesi prescription volume increased approximately 4% in the second quarter of 2023 compared to the first quarter of 2023, and decreased approximately 4.5% in the second quarter of '23 compared to the second quarter of 2022. Prescription volume differs from invoiced sales volume, which reflects among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels. Loss from operations increased by $1.6 million from $6.5 million in the quarter ended June 30 2022 to $8.1 million during the same period in 2023, largely from increased research and development expenses related to the clinical trials for CIOB and other indications. Non-GAAP recurring EBITDA for the second quarter of 2023 and the second quarter of 2022 were a net loss of $7.8 million and $5.3 million, respectively. Net loss attributable to common shareholders increased by approximately $2.8 million from $9.4 million in the quarter ended June 30, 2022 to $12.2 million in the same period in 2023. That concludes my recap of high-level financials for the second quarter of 2023. And I will now hand the discussion back to Lisa Conte.

Thank you, Carol. We at Jaguar and our family companies are highly, highly energized about all our important initiatives underway in 2023 and the culmination of these late-stage clinical events, and what this can mean for patients and all that follows from that. We have no questions that have come in, unless I have screwed up my access to them, but I believe we have no questions. So, with that, we will conclude our call for today. Thank you all who have listened and participated and support Jaguar. Have a good day.

Thank you. This will conclude today's conference. You may disconnect at this time. And thank you for your participation. End of Q&A: